Table 3.
Relationship of covariates to blood glucose and HbA1c measurements
| Glucose (mg/dl) | HbA1c (%) | |||||
| Variables | LS mean ± SE | (95% CI) | P value | LS mean ± SE | (95% CI) | P value |
| Sex | 0.2268 | 0.8062 | ||||
| Female | 107.80 ± 1.34 | (105.15, 110.44) | 5.51 ± 0.10 | (5.31, 5.71) | ||
| Male | 109.70 ± 1.07 | (107.58, 111.81) | 5.48 ± 0.07 | (5.33, 5.64) | ||
| Age, years | 0.075 | 0.3041 | ||||
| 20–49 | 105.09 ± 2.10 | (100.96, 109.22) | 5.33 ± 0.15 | (5.01, 5.64) | ||
| 50–59 | 108.83 ± 1.75 | (105.38, 112.27) | 5.44 ± 0.13 | (5.17, 5.71) | ||
| 60–69 | 109.69 ± 1.43 | (106.88, 112.51) | 5.62 ± 0.10 | (5.42, 5.83) | ||
| 70< | 111.37 ± 1.32 | (108.77, 113.97) | 5.61 ± 0.09 | (5.42, 5.79) | ||
| Medication | 0.4579 | 0.6887 | ||||
| candesartan cilexetil | 110.93 ± 1.31 | (108.34, 113.51) | 5.62 ± 0.10 | (5.41, 5.82) | ||
| losartan potassium | 107.73 ± 2.01 | (103.77, 111.69) | 5.52 ± 0.12 | (5.28, 5.77) | ||
| olmesartan medoxomil | 106.99 ± 2.24 | (102.58, 111.40) | 5.37 ± 0.15 | (5.06, 5.68) | ||
| telmisartan | 108.57 ± 2.16 | (104.31, 112.83) | 5.43 ± 0.16 | (5.10, 5.76) | ||
| valsartan | 109.51 ± 1.56 | (106.44, 112.59) | 5.55 ± 0.12 | (5.30, 5.81) | ||
| Treatment duration | <.0001 | 0.6014 | ||||
| 0 = "Baseline" | 111.98 ± 1.16 | (109.70, 114.27) | reference* | 5.51 ± 0.07 | (5.37, 5.66) | reference* |
| 1 = "~3 M" | 105.86 ± 1.13 | (103.64, 108.09) | <.0001* | 5.50 ± 0.07 | (5.35, 5.65) | 0.8209* |
| 2 = "3~6 M" | 107.78 ± 1.48 | (104.87, 110.69) | 0.0081* | 5.44 ± 0.08 | (5.28, 5.61) | 0.2582* |
| 3 = "6~12 M" | 109.36 ± 1.63 | (106.16, 112.56) | 0.1308* | 5.54 ± 0.08 | (5.37, 5.70) | 0.7457* |
Abbreviations: HbA1c, hemoglobin A1c; LS means, least squares means; SE, standard error; CI, confidence interval.
*Dunnett-Hsu post-hoc analysis.